The Rise of China's Biotech Industry: A Game-Changer for the Global Market

China's biotech industry is rapidly growing, with significant implications for the global market. The US government's response to this growth is a key factor in shaping the industry's future.

TL;DR
• China's biotech industry is rapidly growing, with significant implications for the global market.
• The US government's response to this growth is a key factor in shaping the industry's future.
• The industry's growth has both risks and benefits, including potential job creation and economic growth.

Summary
The biotech industry has become increasingly dependent on China, which has developed into a critical back office for the global biotech supply chain. Cities like Shanghai, Suzhou, Beijing, Shenzhen, and Guangzhou have developed dense life-science clusters, with over 1,700 biomedical companies in Zhangjiang Science City, Shanghai, including major operations of pharmaceutical companies like Boehringer Ingelheim, Pfizer, and AstraZeneca.

The financial pressures facing life sciences companies have forced the biotech ecosystem to look east. The cost of developing new drugs is high, with the average cost for a big pharma company to develop a drug in 2024 being $2.23 billion. Biotech startups face similar challenges, with a median investment of $304.1 million needed to independently develop and commercialize an innovative FDA-approved biologic product between 2017-2023.

Some key insights include:
• China has become a hub for synthesizing small-molecule compounds, running preclinical and clinical programs, and originating novel drugs.
• The country's clinical research ecosystem has matured rapidly, with nearly one third of the world's clinical trials conducted in China in 2024.
• China's lower cost operations, larger volume of patients available for recruitment, and integrated data infrastructure make it an attractive location for conducting research.
• Large pharmaceutical companies are licensing IP assets from Chinese companies at a increasing rate, with the value of drugs licensed from China to the West reaching $48 billion in 2024.

The BIOSECURE Act, passed by the U.S. government in December 2025, restricts U.S. federal agencies from purchasing biotechnology products or services from 'biotechnology companies of concern,' and from awarding contracts or grants to companies that rely on those firms in their supply chains. This regulatory shift sends a clear message that biotechnology has moved squarely into the realm of national security.

As the biotech industry continues to evolve, it's essential to consider the implications of China's growing presence and the US government's response to this growth.